ESCC cells after DPP3 knockdown exhibited higher sensitivity toward T-BHP (Figure 6A,F), cisplatin (Figure 6B,G), and paclitaxel (Figure 6E,J), but not carboplatin (Figure 6C,H). Here, DPP3 is linked to esophageal squamous cell carcinoma.